PANOBINOSTAT LACTATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for panobinostat lactate and what is the scope of freedom to operate?
Panobinostat lactate
is the generic ingredient in one branded drug marketed by Secura and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.Panobinostat lactate has sixty-seven patent family members in forty countries.
There is one drug master file entry for panobinostat lactate.
Summary for PANOBINOSTAT LACTATE
International Patents: | 67 |
US Patents: | 2 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Drug Master File Entries: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 21 |
Clinical Trials: | 1 |
Patent Applications: | 58 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for PANOBINOSTAT LACTATE |
DailyMed Link: | PANOBINOSTAT LACTATE at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for PANOBINOSTAT LACTATE
Generic Entry Date for PANOBINOSTAT LACTATE*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for PANOBINOSTAT LACTATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Abdullah Khan | Phase 1 |
US Patents and Regulatory Information for PANOBINOSTAT LACTATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Secura | FARYDAK | panobinostat lactate | CAPSULE;ORAL | 205353-003 | Feb 23, 2015 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Secura | FARYDAK | panobinostat lactate | CAPSULE;ORAL | 205353-002 | Feb 23, 2015 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Secura | FARYDAK | panobinostat lactate | CAPSULE;ORAL | 205353-003 | Feb 23, 2015 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Secura | FARYDAK | panobinostat lactate | CAPSULE;ORAL | 205353-001 | Feb 23, 2015 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PANOBINOSTAT LACTATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Secura | FARYDAK | panobinostat lactate | CAPSULE;ORAL | 205353-003 | Feb 23, 2015 | ⤷ Try a Trial | ⤷ Try a Trial |
Secura | FARYDAK | panobinostat lactate | CAPSULE;ORAL | 205353-003 | Feb 23, 2015 | ⤷ Try a Trial | ⤷ Try a Trial |
Secura | FARYDAK | panobinostat lactate | CAPSULE;ORAL | 205353-001 | Feb 23, 2015 | ⤷ Try a Trial | ⤷ Try a Trial |
Secura | FARYDAK | panobinostat lactate | CAPSULE;ORAL | 205353-001 | Feb 23, 2015 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for PANOBINOSTAT LACTATE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Canada | 2617274 | UTILISATION D'INHIBITEURS HDAC POUR LE TRAITEMENT DU MYELOME (USE OF HDAC INHIBITORS FOR THE TREATMENT OF MYELOMA) | ⤷ Try a Trial |
European Patent Office | 1912640 | UTILISATION D'INHIBITEUR HDAC PANOBINOSTAT POUR LE TRAITEMENT DU MYÉLOME (USE OF THE HDAC INHIBITOR PANOBINOSTAT FOR THE TREATMENT OF MYELOMA) | ⤷ Try a Trial |
Mexico | 2008001610 | USO DE INHIBIDORES DE HDAC PARA EL TRATAMIENTO DE MIELOMA. (USE OF HDAC INHIBITORS FOR THE TREATMENT OF MYELOMA.) | ⤷ Try a Trial |
Japan | 2015164968 | N−ヒドロキシ−3−[4−[[[2−(2−メチル−1H−インドール−3−イル)エチル]アミノ]メチル]フェニル]−2E−2−プロペンアミドの多形 (POLYMORPH OF N-HYDROXY-3-[4-[[[2-(2-METHYL-1H-INDOLE-3-YL)ETHYL]AMINO]METHYL]PHENYL]-2E-2-PROPENE AMIDE) | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for PANOBINOSTAT LACTATE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1318980 | CR 2015 00068 | Denmark | ⤷ Try a Trial | PRODUCT NAME: PANOBINOSTAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER PANOBINOSTATLAKTAT; REG. NO/DATE: EU/1/15/1023 20150901 |
1318980 | 1590070-7 | Sweden | ⤷ Try a Trial | PRODUCT NAME: PANOBINOSTAT OR A PHARMACEUTICALLY ACCEPTABLE SALTTHEREOF; REG. NO/DATE: EU/1/15/1023 20150901 |
1912640 | C20160001 00181 | Estonia | ⤷ Try a Trial | PRODUCT NAME: PANOBINOSTAAT;REG NO/DATE: EU/1/15/1023 01.09.2015 |
1318980 | SPC/GB15/085 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: PANOBINOSTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: UK EU/1/15/1023 20150901 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |